Skip to content

Study · Not a test of the peptide alone · 2025

3 results

Microenvironment Remodeling Microgel Repairs Degenerated Intervertebral Disc via Programmed Delivery of MicroRNA-155.

Guo C, Liu Y, Ma F, Xu X, Zhang W, Zhao Z, Wang Y, Kong Q

ACS applied materials & interfaces13 Jan 2025Cited by 7 (Europe PMC)

PMID39804788 (opens in a new tab)DOI10.1021/acsami.4c18801 (opens in a new tab)PepBankPUB-39804788
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    A lactic acid-capturing microgel carrying miR-155 and SS31 promoted intervertebral disc regeneration.

    In plain wordsA microgel carrying miR-155 and SS31 promoted disc regeneration. The abstract does not name the model.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseIntervertebral disc regeneration
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The microgel system effectively promoted IVD regeneration by alleviating the acidic microenvironment
    1 context sentence
    Summary · context
    In this study, a lactic acid-capturing microgel carrying a functionalized miRNA-155 nanocarrier was designed for IVD regeneration. microRNA-155 was loaded into the NPC-targeted nanogel via host-guest binding.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    A lactic acid-capturing microgel carrying miR-155 and SS31 prevented apoptosis of nucleus pulposus cells.

    In plain wordsA microgel carrying miR-155 and SS31 reduced disc cell death. The abstract does not name the model.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNucleus pulposus cell apoptosis
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    preventing NPC apoptosis.
    1 context sentence
    Summary · context
    In this study, a lactic acid-capturing microgel carrying a functionalized miRNA-155 nanocarrier was designed for IVD regeneration. microRNA-155 was loaded into the NPC-targeted nanogel via host-guest binding.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03LabNot a test of Elamipretide (SS-31) aloneOther designMechanism

    SS31 released from the nanogel network of a miR-155 microgel regulated mitochondrial metabolism; the abstract gives no direction.

    In plain wordsSS31 released from a microgel carrying miR-155 changed mitochondrial metabolism. The direction and model are not stated.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedMitochondrial metabolism regulation by released SS31
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Musculoskeletal

    Source sentences

    Summary
    Moreover, SS31, which dissociated from the nanogel network, had the ability to regulate mitochondrial metabolism.
    1 context sentence
    Summary · context
    In this study, a lactic acid-capturing microgel carrying a functionalized miRNA-155 nanocarrier was designed for IVD regeneration. microRNA-155 was loaded into the NPC-targeted nanogel via host-guest binding.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.